Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 08, 2021

Outcomes With Nivolumab Plus Ipilimumab in Active Melanoma Brain Metastases

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study
Lancet Oncol 2021 Nov 10;N/A(N/A)1-13, HA Tawbi, PA Forsyth, FS Hodi, AP Algazi, O Hamid, CD Lao, SJ Moschos, MB Atkins, K Lewis, MA Postow, RP Thomas, J Glaspy, S Jang, NI Khushalani, AC Pavlick, MS Ernstoff, DA Reardon, R Kudchadkar, A Tarhini, C Chung, C Ritchings, P Durani, M Askelson, I Puzanov, KA Margolin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading